טוען...
The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
BACKGROUND: Natalizumab is efficacious in the treatment of relapsing-remitting multiple sclerosis. All patients receive the same treatment regimen of 300 mg every 4 weeks, despite differences in pharmacokinetics between individual patients. OBJECTIVE: To give neurologists insight into natalizumab co...
שמור ב:
| הוצא לאור ב: | Mult Scler |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5971363/ https://ncbi.nlm.nih.gov/pubmed/28485678 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458517708464 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|